Kedlian, Veronika R. http://orcid.org/0000-0001-6563-0829
Wang, Yaning
Liu, Tianliang http://orcid.org/0000-0002-7872-4370
Chen, Xiaoping
Bolt, Liam http://orcid.org/0000-0001-7293-0774
Tudor, Catherine http://orcid.org/0000-0003-2093-9683
Shen, Zhuojian
Fasouli, Eirini S. http://orcid.org/0000-0003-1621-3396
Prigmore, Elena http://orcid.org/0000-0001-8870-0316
Kleshchevnikov, Vitalii
Pett, Jan Patrick http://orcid.org/0000-0002-5249-444X
Li, Tong http://orcid.org/0000-0002-8240-4476
Lawrence, John E. G.
Perera, Shani
Prete, Martin
Huang, Ni
Guo, Qin
Zeng, Xinrui
Yang, Lu http://orcid.org/0000-0002-2694-1189
Polański, Krzysztof http://orcid.org/0000-0002-2586-9576
Chipampe, Nana-Jane http://orcid.org/0000-0002-8802-0473
Dabrowska, Monika
Li, Xiaobo
Bayraktar, Omer Ali http://orcid.org/0000-0001-6055-277X
Patel, Minal
Kumasaka, Natsuhiko
Mahbubani, Krishnaa T. http://orcid.org/0000-0002-1327-2334
Xiang, Andy Peng http://orcid.org/0000-0003-3409-5012
Meyer, Kerstin B. http://orcid.org/0000-0001-5906-1498
Saeb-Parsy, Kourosh http://orcid.org/0000-0002-0633-3696
Teichmann, Sarah A. http://orcid.org/0000-0002-6294-6366
Zhang, Hongbo http://orcid.org/0000-0002-4081-5752
Funding for this research was provided by:
Wellcome Trust (WT211276/Z/18/Z, WT206194)
Wellcome Trust (220540/Z/20/A)
National Natural Science Foundation of China (32000840, 31871370)
Natural Science Foundation of Guangdong Province (2021A1515012065)
EC | Horizon 2020 Framework Programme (101026233)
Article History
Received: 20 November 2023
Accepted: 19 March 2024
First Online: 15 April 2024
Competing interests
: In the past 3 years, S.A.T. has consulted for or been a member of scientific advisory boards at Qiagen, Sanofi, GlaxoSmithKline and ForeSite Labs. She is a co-founder and an equity holder of TransitionBio and EnsoCell and a SAB member of Element Biosciences. She is a part-time employee at GlaxoSmithKline. The remaining authors declare no competing interests.